Several studies have shown that CD33- and CD123-directed CARs engineered on CIK cells have efficacy against AML in vitro and in vivo, but with increased toxicity in hematopoietic tissues when targeting CD33 compared to CD123 [102,103,104,105,106]. The gene discussed is CD33; the disease is acute myeloid leukemia.